当前位置: X-MOL首页SCI期刊查询及投稿分析系统 › BioDrugs杂志
BioDrugs
基本信息
期刊名称 BioDrugs
BIODRUGS
期刊ISSN 1173-8804
期刊官方网站 https://www.springer.com/40259
是否OA No
出版商 Adis International Ltd
出版周期 Bimonthly
文章处理费 登录后查看
始发年份 1994
年文章数 62
影响因子 5.4(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 IMMUNOLOGY 免疫学3区
ONCOLOGY 肿瘤学3区
PHARMACOLOGY & PHARMACY 药学2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 12.6 1.796 1.506
Medicine
Pharmacology (medical)
10/272 96%
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
24/313 92%
Biochemistry, Genetics and Molecular Biology
Biotechnology
29/311 90%
补充信息
自引率 5.6%
H-index 60
SCI收录状况 Science Citation Index Expanded
官方审稿时间 登录后查看
网友分享审稿时间 数据统计中,敬请期待。
接受率 登录后查看
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1173-8804%5BISSN%5D
投稿指南
期刊投稿网址 https://www.editorialmanager.com/bdra
收稿范围
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. The Journal includes:

Definitive reviews on topics relating to the development and use of biotechnology in healthcare and the management of disease.
Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles on the clinical development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products.
Leading/Current Opinion articles providing an overview of contentious or emerging issues and key regulatory and ethical issues.
Adis Drug Evaluations reviewing the properties and place in therapy of biotechnology-based drugs. 
Adis Biosimilar Briefs summarizing key characteristics and clinical use of biosimilar drugs.
收录体裁
Leading Article
Review Article
Current Opinion
Systematic Review
Original Research
Letter to the Editor
Editorial/Commentary
投稿指南 https://link.springer.com/journal/40259/submission-guidelines
投稿模板
参考文献格式
编辑信息

Editor (Adis International Limited, Auckland, New Zealand):

Kathy Fraser

Section Editors (Adis International Limited, Auckland, New Zealand):

Martin Chopra

Rod McNab

David Williamson

Editorial Board:

L. Bergmann, Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany

G.D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA

T.R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA

T.M. Ganey, Vivex Biomedical, Atlanta, GA, USA

A. Ganser, Hannover Medical School, Hannover, Germany

H-P. Gerber, 3T Biosciences, Palo Alto, CA, USA

T.J. Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands

B. Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany

F. Guilhot, Université de Poitiers, Poitiers, France

W.H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA

P. Moingeon, Stallergenes, Paris, France

D. Müller, Universitat Stuttgart, Stuttgart, Germany

W. Park, Inha University Medical School, Incheon, Republic of Korea

C. Picado, Hospital Clinic de Barcelona, Barcelona, Spain

T. Schirrmann, YUMAB GmbH, Braunschweig, Germany

S. Sharfstein, SUNY Polytechnic Institute, Albany, NY, USA

C.A. Stein, City of Hope Medical Center, Duarte, CA, USA

R.C. Stevens, University of Southern California, Los Angeles, CA, USA

W.R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA

B.A. Sullenger, Duke University Medical Center, Durham, NC, USA

J. Terrett, Crispr Therapeutics, Inc., Cambridge, MA, USA

G. Trifirò, University of Messina, Sicily, Italy

P. Trzonkowski, Medical University of Gdansk, Gdansk, Poland

J.W. Van der Meer, University Medical Center St Radboud, Nijmegen, the Netherlands

G. Woollett, Avalere Health, Washington, DC, USA

我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug